Back to Geopolitics Explained

IntermediateUpdated 2026/08/08

What Do AI Controls Actually Control — Chips, Models, or Uses?

All three, with very different odds. Chips are controllable because they are physical, cross a border, and come from few production lines. Model weights are files — once copied there is no second chance. Uses, for the most part, only become visible after the fact.

Read this first: Never Sold to America — So Why Do Export Controls Still Reach You?

What are the layers of AI control?

Roughly four, bottom to top: compute hardware, cloud access, model weights, and downstream applications. Each is regulated by someone, but enforceability differs enormously — and policy debate often fails to say which layer it is about.

The bottom layer is chips and manufacturing equipment, and it fits traditional export controls perfectly: physical goods, crossing customs, from a supply base concentrated enough to track shipment by shipment.

Above it is cloud access. The hardware stays home while the user is abroad — nothing is exported, yet the capability is. Recent rules have therefore started treating who may log in as a control question.

Above that are model weights: the trained parameters themselves. Weights are a file, and that single fact makes their control logic fundamentally unlike the two layers below.

At the top are applications — who uses a model for what. This layer is closest to actual harm and hardest to identify in advance: the same request, in a different context, is a different act.

Why does regulation almost always start with compute?

Because it is the only layer with everything traditional control requires: the item can be defined, its movement observed, its origin traced. Advanced-node chips come from a handful of production lines, and the equipment that builds those lines from fewer suppliers still — controllability rises as you move upstream.

It is also a textbook dual-use problem: the same accelerators may run drug design or military simulation, and the spec sheet cannot tell them apart. So the control is not really on the chips but on who may obtain them.

The approach has a boundary, though. Controlling hardware controls the ability to train new models; it does nothing about models already trained — and those already exist as files. That is the key to the next question.

How are model weights fundamentally unlike chips?

In a sentence: a chip that slips through can still be chased; weights cannot. Physical goods retain a quantity, a location, and a dependence on maintenance and spares, so mistakes can be mitigated afterwards. Once weights are copied, the copies are unlimited, their locations unknown, and they need no further support to work.

That concentrates the control point almost entirely on the moment of release. Before release the decision belongs to the developer; after it, what remains is restricting services, assigning liability, and watching usage — none of which retrieves the file.

Which is why the open-weights argument is not simply “is openness good”. Openness brings auditability, independent research, and a more distributed set of supply options — all real benefits — and it is also the one choice that cannot be undone. Both sides are right; one is describing the gain and the other the absence of a way back.

A model served through an API keeps one thing by contrast: use can be observed, and it can be stopped. This is why many frameworks treat served models and released weights separately — the risks differ in kind, not in degree.

Why is biological risk so often carved out for separate treatment?

Because it is one of the few risks where once is enough. Most AI misuse accumulates — fraud, influence operations, and code vulnerabilities are problems of volume that can be corrected while being observed. Biological risk is not: a single success can be unrecoverable, so correcting afterwards is not available.

The other reason is that its gates are elsewhere. Causing real harm takes more than information — it takes material access, laboratory equipment, and tacit skill. So the effective line of defence often sits on the supply side rather than the model side: screening orders for synthesised sequences, controlling laboratory access. It is work model developers and the biotech supply chain have to do together; either alone leaves a gap.

It also explains why rules here have moved faster than in other AI debates: there is an existing regime to attach to. Biosecurity already has a control framework, and the new question is how to fit models into it rather than how to build one from nothing.

Why should this matter to people who do not build AI?

Because these rules land on use, not only on development. Regimes already exist that treat who may access a model service as in scope, including foreign nationals inside the country — which is not an AI company’s problem but an HR and compliance problem for any firm running a cross-border team on a cloud model.

The second reason is procurement. As the logic of economic security extends to AI, who built this model, where it runs, and where the data stays will become required fields in tender documents, much as security questionnaires did before. Knowing your own answers early is far cheaper than being asked cold.

The third is the most practical: which layer is regulated determines how you are affected. Hardware-layer controls hit cost and lead time; service-layer controls hit user lists and audit obligations; the weights argument decides whether you can deploy on your own infrastructure at all. These get compressed into the phrase “AI regulation”, and they land on entirely different parts of an operation.